InvestAcure has developed a formidable plan to end the roadblock imposed by insufficient capital to fund clinical trials necessary to discover effective cures for Alzheimer Disease. With so many major pharmaceutical companies leaving the space, it is even more imperative that we activate this approach immediately if we are to bring cures to families.

Many advances in research are not pursued by larger drug companies whose economic models favor palliative care (long-term repeat drug sales) over cures and drugs over diagnostics while smaller companies struggle to attract investment. InvestAcure's Common Need Investment model has the potential to alleviate some of this investment bottleneck. 70 million US adults have a relative with Alzheimer's. If a small percentage of this affinity group invest their spare-change, billions of dollars will be freed to fund approaches that might otherwise be neglected.

We can cure Alzheimer’s in our mice every week, but when it comes to clinical research where real progress needs to be made to cure people, there is simply no funding available.

We can't afford to sit idly by as research is stalled by a profit-driven agenda. With InvestAcure, we have a real solution to speed the path to a cure, by transitioning ownership of drug companies to millions of spare change investors committed to curing Alzheimer's.

The idea of having millions of people impacted by Alzheimer's join together as spare change investors, who own stock in drug companies, represents an innovative and potentially game-changing solution to the "valley of death" problem in the pharmaceutical industry. If scaled to full potential, it can help ensure that smaller scientist led drug companies to have the investment and support of their shareholders needed to pursue the development of cutting edge scientific breakthroughs into lifesaving drugs. I’m excited to join the team and do my part in realizing this world-changing vision.

When Harvey Pitt, former chairman of the SEC, visited MIT and mentioned InvestAcure as an example of a company using Finance for good, I was intrigued by the idea as it both spoke to my core values and was inspired by the research of my colleague, MIT Professor Andrew Lo, on the growing investment bottleneck stifling the development of lifesaving cures. I believe that Common Need Investment of spare change by millions committed to curing Alzheimer's is a potentially game-changing solution to that bottleneck. If successfully implemented, it can speed the development of lifesaving drugs and save countless lives. I'm excited to be an advisor to the InvestAcure team and do my part to help make this a reality.